盐酸埃克替尼治疗晚期非小细胞肺癌临床观察

Clinical Observation of Icotinib Hydrochloride for Patients with Advanced Non- small Cell Lung Cancer

目的观察盐酸埃克替尼治疗晚期非小细胞肺癌的近期疗效及毒副反应。方法回顾分析2009年3月～2012年1月北京胸科医院肿瘤内科收治的晚期非小细胞肺癌患者59例，均口服盐酸埃克替尼单药治疗。对近期疗效，毒副反应进行分析。结果全组59例患者中无CR病例，PR：27例（45．8％），SD：17例（28．8％），PD：15例（25．4％）。总有效率（ORR）：45．8％（27／59），疾病控制率（DCR）：74．6％（44／59）。EGFR突变患者总的ORR：73．9％（17／23）；DCR：95．7％（22／23）。症状缓解率：61％（36／59），主要缓解的症状为咳嗽、呼吸困难及疼痛。治疗相关毒副反应主要为皮疹35．6％（21／59）、腹泻15.3％（9／59）。本组盐酸埃克替尼治疗的疗效与ECOG评分、吸烟史、EGFR突变、皮疹相关，差异有统计学意义，P值〈0．05。结论盐酸埃克替尼单药治疗晚期非小细胞肺癌近期疗效肯定，对于EGFR突变患者有效蜜雨高．治疗相姜的毒副后商掂梆．

objective To explore the efficacy and side effects of icotinib hydrochloride in the treatment of patients with advanced non-small cell lung cancer （NSCLC）. Methods We analyzed retrospectively the efficacy and side effects of icotinib hydrochloride for 59 patients with advanced NSCIC from March 2009 to January 2012 in Beijing Chest Hospital. Results Of 59 patients, partial response（PR）rate was 45.8 %, stability of disease （SD） 28.8%, objective response rate （ORR） 45.8 %, disease control rate （DCR） 74.6% .In patients with EGFR active mutations, ORR was 73.9%（17/23）, DCR 95.7% （22/23） . Symptom remission rate was 61% （36/59） mainly including cough,dyspnea and pain. Common drug-related adverse events were mild skin rash （35.6%） and diarrhea （15.3%）. The response of icotinib was associated with ECOG PS, smoking history, EGFR mutation status and skin rash （P 〈 0.05）. Conclusions Monotherapy with icotinib hydrochloride is effective and tolerable for patients with advanced NSCLC, with better response rate for those with EGFR active mutations.